Ambalal Sarabhai Enterprises Limited Overview
Ambalal Sarabhai Enterprises is a small, family-controlled holding-and-operating company and one of India's oldest pharmaceutical names. Today it is a diversified micro-cap with consolidated revenue of about INR 202 crore (FY2026). It works almost entirely through subsidiaries and joint ventures across two reported segments. Pharmaceuticals (about 55% of FY2026 revenue) covers niche APIs such as Amphotericin B at Synbiotics, oncology and synthetic APIs at Asence Pharma, branded domestic formulations in oncology, fertility and women's health at Sarabhai Chemicals, effervescent and Vitamin C products, and international trading through Asence Inc. (USA). Electronics (about 45%) covers Systronics laboratory and analytical instruments and Telerad broadcast-equipment distribution. The company also holds a minority interest in the CoSara molecular-diagnostics JV with Nasdaq-listed Co-Diagnostics, which is exploring a US SPAC listing. ASE combines a legacy brand, a rebuilt balance sheet and several optionality-driven assets with thin operating margins, volatile earnings, low promoter ownership (31.35%) and no dividend.
Company's own description
In its latest Directors' Report (FY2025-26), management describes a strategy of operating through focused subsidiaries and joint ventures. It says this structure supports group operating efficiency, business development and long-term growth. The report says the group has 8 subsidiaries, 2 joint ventures and 1 associate. It highlights:
Asence Inc: (wholly owned, USA): supplies finished dosage forms and APIs to international markets. It focuses on product registrations, partnerships and niche products for regulated and semi-regulated markets.
Asence Pharma Pvt. Ltd: continued scaling up its oncology and synthetic API facility at Ranoli, Vadodara. It received the demerged Oncology and Pro-Fertility division of Sarabhai Chemicals.
Systronics (India) Ltd: operates the Systronics division, which makes and markets analytical, laboratory and test-and-measurement instruments across India, and the Telerad division, which handles broadcast equipment.
Sarabhai Chemicals (India) Pvt. Ltd: domestic branded pharmaceuticals in oncology, fertility, women's healthcare and other specialty therapies.
- Group investments described as strengthening manufacturing capability, regulatory compliance and future growth.
The company's exchange profile describes ASE as a pharmaceutical healthcare company that, through group companies, makes and markets pharmaceutical, molecular-diagnostic and electronics products in India and abroad (Screener, citing the annual report). Groww's company summary, drawn from company disclosures, adds two points. Vovantis, described as a JV, operates a USFDA-approved plant at Ranoli focused on US and European markets. Synbiotics is a USFDA-inspected maker of the antifungal API Amphotericin B.
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Legal/operating structure | A listed parent with minimal standalone operations: standalone revenue of about INR 4 crore a year (Screener standalone), and standalone Q4 FY2026 revenue of INR 1.52 crore (Dion Global). Almost all revenue sits in subsidiaries. |
| Revenue model mix | About 100% product sales across API, formulations, instruments and distributed broadcast equipment, plus small service/AMC income in electronics. No subscription or licensing revenue is disclosed. |
| Pharma model | Mixed. API manufacture (B2B to formulators, India and export), contract/third-party manufacturing, branded generics sold to doctors and pharmacies in India, and trading/export through Asence Inc. |
| Electronics model | Mixed. Own-manufactured analytical and lab instruments sold to labs, educational institutions, industry and government (Systronics), and a distribution/reseller model for broadcast and pro-AV equipment (Telerad). |
| Value-chain position | Upstream in pharma (fermentation-derived and synthetic APIs). Mid-stream in formulations. Downstream marketing in domestic branded products. In electronics, the company acts as both an OEM and a distributor. |
| Customer types | Pharmaceutical formulators and hospitals (API); doctors, pharmacies and hospitals (branded formulations); international distributors (Asence Inc.); educational and research labs, QC labs and government institutions (Systronics); broadcasters and production houses (Telerad). |
| End-markets | Anti-infectives (antifungals), oncology, fertility/IVF, women's health, nutraceuticals (Vitamin C/effervescent), veterinary (per MarketInOut description), laboratory instrumentation, broadcast and pro-video, and molecular diagnostics through the CoSara JV. |
Independent characterisation
ASE is best understood as a legacy-brand micro-conglomerate in a multi-year rebuild. The founding family has spent roughly three decades settling legacy liabilities and building new vehicles. In an interview, Mohal Sarabhai described Asence as a deliberately fresh "springboard" company. The standalone entity still carries negative reserves: net worth was INR 59.48 crore against equity capital of INR 76.63 crore, with reserves of minus INR 17.15 crore (IIFL standalone balance sheet, March 2026). Value is concentrated in the subsidiaries and in equity-accounted stakes.
The economic engine is modest. Consolidated revenue has moved within a INR 163–202 crore band since FY2021. Operating margins are mid-single-digit. FY2022 was the exception, when Amphotericin B demand during India's 2021 mucormycosis outbreak drove profit to INR 47 crore. Earnings are heavily influenced by other income and equity-accounted results. The equity story therefore rests mostly on optionality: the Ranoli oncology API plant ramp, regulated-market exports, the CoSara SPAC, and the electronics business's steady profitability.
Strategy
Stated strategy themes (FY2025-26 Directors' Report and company profile)
-
Focused subsidiaries and JVs. Each business is run as a separate vehicle with its own focus. Management says this improves efficiency and partnering ability.
-
Disease-based solutions. Emphasis on APIs, molecular diagnostics and niche effervescent products, with technology capabilities applied across healthcare and electronics (Groww summary of company disclosure).
-
Regulated-market expansion. Asence pursues registrations and partnerships in regulated and semi-regulated markets. Vovantis' USFDA-approved plant targets the US and EU.
-
Oncology API scale-up. Continued ramp of the Ranoli oncology and synthetic API facility.
-
Domestic specialty brands. Sarabhai Chemicals focuses on oncology, fertility and women's health. The Oncology and Pro-Fertility division was demerged into Asence Pharma for sharper focus.
-
Manufacturing and compliance investment. Group investments are framed as strengthening manufacturing capabilities and regulatory compliance.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Pharma Committee of the board | 13 Aug 2025 | Board-level committee to oversee pharma strategy and operations | Formed |
| CoSara SPAC exploration | 5 Nov 2025 | Co-Dx appointed Maxim Group as exclusive adviser for a US SPAC or similar listing of CoSara | Exploratory; no terms or timetable disclosed |
| CoSara PCR Pro regulatory/manufacturing readiness | FY2025–26 | Co-Dx reports regulatory milestones in India for the PCR Pro instrument and manufacturing readiness | In progress; Co-Dx targeted commercialisation in 2026 |
| Demerger of Oncology and Pro-Fertility division to Asence Pharma | FY2026 | Internal reorganisation | Completed per FY2026 DR |
| Ranoli API plant scale-up | Ongoing | Volume ramp at the oncology/synthetic API plant | Ongoing |
| Section 185 loan authorisations | 30 Jul 2026 (AGM) | Shareholders authorised loans to three related entities | Approved |
| Shareholder plant visit, Ranoli | Rescheduled to 1 Dec 2026 | Investor engagement initiative; registration closes 13 Nov 2026 | Scheduled |
Medium-term targets and guidance
Not publicly disclosed. ASE does not issue financial guidance, hold earnings calls or publish medium-term targets. No sustainability or ESG commitments with quantified targets were identified. No formal cost-reduction programme has been announced.
Products & Services
ASE does not publish a product-level catalogue with prices or launch dates in its statutory filings. The table below lists every product line identifiable from company disclosures and reputable profiles. Brand-level SKU names are not publicly disclosed in the sources reviewed.
Pharmaceuticals
| Product line | Entity | Description / capability | Target customer | Year / status | Pricing model |
|---|---|---|---|---|---|
| Amphotericin B (API) | Synbiotics | Fermentation-derived polyene antifungal API for conventional, lipid and liposomal formulations. Described as India's only Amphotericin B API manufacturer (2021 BSE filing). USFDA-inspected site. | Formulators (India and export), government tenders during outbreaks | Long-running; capacity ramp May 2021 | B2B contract/spot; not disclosed |
| Oncology APIs | Asence Pharma | High-potency/oncology and synthetic APIs from the Ranoli plant | Formulators, regulated and semi-regulated markets | Plant commissioned June 2023; scaling up (FY2026 DR) | — |
| Synthetic APIs (non-oncology) | Asence Pharma | General synthetic API capacity at Ranoli | Formulators | 2023 onward | — |
| Finished dosage forms (export) | Asence Inc. | Sourcing and supply of FDFs and APIs to international markets; product registrations | International distributors, institutional buyers | Ongoing | Trading margin |
| Oncology formulations (domestic, branded) | Sarabhai Chemicals → Asence Pharma (demerged division) | Branded oncology products marketed to oncologists | Hospitals, oncologists, pharmacies | Ongoing | Branded MRP; not disclosed |
| Fertility / Pro-fertility formulations | Sarabhai Chemicals → Asence Pharma | Infertility and IVF-support products | IVF clinics, gynaecologists | Ongoing | — |
| Women's healthcare / uro-gynaec | Sarabhai Chemicals | Specialty women's-health formulations | Gynaecologists | Ongoing | — |
| Vitamin C coated products | Sarabhai M. Chemicals | Coated ascorbic acid for nutraceutical and pharma use | Formulators, nutraceutical brands | Since August 2019 | B2B |
| Effervescent formulations | Group (Vovantis/Sarabhai M.) | Niche effervescent products, highlighted as a focus area | Brands, export | Ongoing | — |
| Novel drug delivery / regulated-market formulations | Vovantis Laboratories (JV) | USFDA-approved plant at Ranoli with focus on US and European markets | Regulated-market partners | Ongoing | — |
| Generics and veterinary products | Suvik Hitek / group | Domestic generics and veterinary products | Distributors, vets | Ongoing | — |
| Molecular diagnostics (PCR Pro instrument and tests) | CoSara Diagnostics (JV) | Co-Dx CoPrimer-based PCR tests and the PCR Pro point-of-care platform for India; Co-Dx reports CoSara regulatory progress and manufacturing readiness for PCR Pro | Hospitals, labs, public-health programmes (including TB) | Commercialisation targeted for 2026 per Co-Dx FY2025 results | — |
Electronics
| Product line | Division | Description / capability | Target customer | Status |
|---|---|---|---|---|
| UV-Visible spectrophotometers (double beam, single beam) | Systronics | Import-substitute analytical instruments | QC labs, pharma, academia, research | Long-running |
| Photofluorimeters / fluorimeters | Systronics | Fluorescence measurement instruments | Labs, education | Long-running |
| Laboratory and analytical instruments (pH meters, conductivity, colorimeters and similar) | Systronics | General lab instrumentation; specific models not disclosed | Educational institutions, industry, government labs | Ongoing |
| Test and measuring instruments | Systronics | Electronic T&M equipment | Industry, education | Ongoing |
| Broadcast, video and audio equipment | Telerad | Distribution/integration of professional broadcast and pro-AV equipment; award-winning regional distributor (West) in 2025 | TV broadcasters, production houses, institutions | Ongoing |
| Service / AMC | Systronics, Telerad | Installation, maintenance and support | Installed base | Ongoing |
Financial Narrative
Basis: Consolidated, INR crore, fiscal years ending 31 March. FY2025 and FY2026 headline lines come from the Directors' Report (FY2025-26). Other lines and years come from StockAnalysis (S&P data, converted from INR million) and Screener, cross-checked against the Directors' Report. Different providers classify income items differently, so "operating income" and "EBITDA" are shown on two bases and labelled.
Income statement
Notes:
-
Directors' Report FY2026: turnover INR 202.27 crore (FY2025: 196.19); other income 15.17 (11.38); total income 217.44 (207.57); finance cost 4.09 (4.26); depreciation 3.94 (4.01); profit before exceptional items 18.90 (11.19); PBT 19.33 (11.83); net profit 17.80 (4.93).
-
No diluted share instruments were identified. Basic and diluted EPS are equal.
Margins and growth
Revenue CAGR: FY2022–FY2026 (4 years): about 0.7%. FY2021–FY2026 (5 years, FY2021 revenue INR 163 crore per Screener): about 4.4%. Screener reports a 5-year sales CAGR of 4.35%.
Quarterly trajectory (INR crore, consolidated)
Sources: Arthneeti/Screener quarterly tables; Capital Market newswire for Q1 FY2027 (sales 43.56, OPM 10.42%, PBDT 6.03, PBT 4.68, NP 3.98).
-
Q1 FY2027 operating profit is derived as 10.42% × 43.56.
-
Q1 FY2027 other income is approximated from total income of INR 45.59 crore (Groww/Univest) minus revenue.
-
Q4 FY2026 PBT: Kotak Neo shows 5.84, Arthneeti shows 6.25. The two sources differ.
Balance sheet
Notes:
-
Total debt is derived as cash plus short-term investments plus net debt (StockAnalysis). MarketsMojo reports consolidated borrowings of INR 51.65 crore at March 2026, likely excluding lease liabilities.
-
The short-term/long-term debt split is not publicly disclosed in the sources reviewed. MarketsMojo indicates short-term borrowings roughly tripled (+200.7%) in FY2026 while long-term borrowings rose about 6%. This implies a mix shift toward working-capital lines.
Shareholders' equity (consolidated, point-in-time): about INR 140 crore (circa March 2025, Simply Wall St); INR 137.5 crore at 30 September 2025 (ScanX, company filing); about INR 158 crore at March 2026 (Screener book value of INR 20.66 per share × 7.663 crore shares).
Standalone net worth: FY2023 INR 37.84 crore; FY2024 40.29; FY2025 48.49; FY2026 59.48 (IIFL). Standalone reserves remain negative (minus INR 17.15 crore in FY2026).
Cash flow
Source: StockAnalysis (S&P). Bajaj Broking shows FY2025 OCF of minus INR 14.39 crore, a minor discrepancy in classification.
Ratios
Notes:
-
The current ratio is computed as current assets / (current assets minus working capital).
-
Net debt/EBITDA on an EBITDA basis of operating income plus D&A: FY2025 = 42.2 / (12.6 + 4.0) = 2.5x; FY2026 = 39.9 / (19.0 + 3.9) = 1.7x.
ROE: FY2026 about 12% (Screener consolidated ROE 12.4%; computed 17.80 / average equity of about 149 = 11.9%); FY2025 about 3.6% (computed). The Screener 3-year average is about 8.1%.
ROCE: FY2026 11.7% (Screener consolidated). ROIC is 3.5% on MarketInOut's TTM basis.
Debt/equity: 0.36x at both March 2025 and March 2026 (Simply Wall St 36.6%; MarketInOut/ScanX 0.36).
Cash conversion cycle: not reliably computable from the disclosures reviewed.
- Receivable days rose from 65 to 82 (Screener, FY2025). Computed FY2026 receivable days are about 100 (55.4 / 202.3 × 365).
Commentary on trends, inflections and drivers
Revenue. Revenue is range-bound. FY2022's INR 197 crore benefited from the Amphotericin B demand spike. FY2023 fell 13.5% as that normalised. FY2024 was flat. FY2025 recovered 13% as Electronics grew and the Ranoli API plant began contributing. FY2026 grew a muted 2.6%. Growth is strongly back-end loaded each year because of Electronics' Q4 seasonality.
Gross margin. Gross margin has been notably stable at 39–41%. This suggests no structural pricing erosion, but also no mix-driven expansion yet from oncology APIs.
Operating leverage. Operating leverage is weak. SG&A rose from INR 26 crore to INR 33 crore over four years, which absorbed most of the gross-profit gains. EBITDA margin before other income bottomed at 3.5% in FY2024, when the new plant's fixed costs hit before revenue, and recovered to 5.9% in FY2026. Q1 FY2027 OPM of 10.4% is the best first quarter in the series and is a possible inflection, though one quarter is not a trend.
Earnings quality. Earnings quality is the central analytical issue. Other income (INR 15.2 crore in FY2026) was about 85% of FY2026 PBT. Screener flags other income of about INR 15.6 crore TTM and a low effective tax rate. The FY2026 tax line was minimal: PBT of INR 19.3 crore produced net profit of INR 17.8 crore, aided by deferred tax assets of INR 3.9 crore. Q1 FY2026's INR 8.22 crore profit was driven by INR 8.4 crore of other income. Q1 FY2027's 52% profit decline came mainly from a 76% fall in other income (ScanX), even as operating profit rose roughly threefold. Investors should separate core operating improvement, which is real, from the volatility of headline profit.
Balance sheet. The balance sheet is leveraged moderately but is creeping up. Net debt rose from about INR 1 crore (FY2022) to INR 40–42 crore (FY2025–26). This reflects Ranoli capex (FY2022–23 capex of INR 36 crore), a working-capital build in FY2025 (receivables jumped INR 21 crore), and lower liquid investments. FY2026 brought partial repair: positive FCF of INR 9 crore and working capital back to positive. Goodwill of INR 24.5 crore (about 15% of equity) has been stable, with one INR 0.14 crore impairment in FY2024.
Shareholder returns. No dividend has been paid in at least ten years (finanzen.ch dividend history 2017–2026 shows zero). The Directors' Report again expressed inability to recommend a dividend for FY2026. Standalone negative reserves constrain distributable profits.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains (entities) | Products / services |
|---|---|---|
Pharmaceuticals | Synbiotics Ltd.; Asence Pharma Pvt. Ltd.; Asence Inc. (USA); Sarabhai Chemicals (India) Pvt. Ltd.; Sarabhai M. Chemicals Ltd.; Suvik Hitek Pvt. Ltd.; equity-accounted Vovantis Laboratories (JV/associate status: see 4.3) and CoSara Diagnostics (JV) | Amphotericin B API; oncology and synthetic APIs; finished dosage forms for export; branded formulations (oncology, fertility, women's health); Vitamin C coated and effervescent products; molecular diagnostics through the JV |
Electronics | Systronics (India) Ltd.: Systronics division and Telerad division | Spectrophotometers, fluorimeters, lab/analytical and test-and-measurement instruments; broadcast, video and audio equipment distribution |
Revenue by Segment
| Segment (INR Cr) | FY2023 | FY2026 |
|---|---|---|
Pharmaceuticals revenue | 101.37 | 110.51 |
Electronics revenue | 68.91 | 91.78 |
Total revenue from operations | 170.28 | 202.27 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2023 | FY2026 |
|---|---|---|
Pharmaceuticals share | 59.5 | 54.6 |
Electronics share | 40.5 | 45.4 |
Segment Result Details
| Segment result (INR Cr) | FY2023 |
|---|---|
Pharmaceuticals | 7.34 |
Electronics | 9.92 |
Total segment results | 17.26 |
Revenue by Segment (Quarterly)
| Segment (INR Cr) | Q1FY2024 | Q1FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|
Pharmaceuticals revenue | 19.83 | 25.46 | 30.34 | 25.26 |
Electronics revenue | 16.27 | 14.87 | 35.15 | 18.30 |
Total | 36.10 | 40.34 | 65.49 | 43.56 |
Results by Segment
| Segment result (INR Cr) | Q1FY2024 | Q2FY2026 |
|---|---|---|
Pharmaceuticals result | -4.95 | -1.21 |
Electronics result | 1.30 | 2.13 |
Group Entities
| Entity | Relationship | Function | Status / note |
|---|---|---|---|
Synbiotics Ltd. | Subsidiary | Amphotericin B API (fermentation); USFDA-inspected; JV partner in CoSara | Received bulk drug division 2010 |
Asence Inc. (USA) | Wholly owned subsidiary | International trading of FDFs and APIs | "Springboard" vehicle |
Asence Pharma Pvt. Ltd. | Subsidiary | Oncology and synthetic API plant, Ranoli (commissioned June 2023); received Oncology and Pro-Fertility division | Scaling up |
Sarabhai Chemicals (India) Pvt. Ltd. | Subsidiary | Domestic branded formulations | Partial demerger to Asence Pharma |
Sarabhai M. Chemicals Ltd. | Wholly owned subsidiary | Vitamin C coated products (since August 2019) | — |
Systronics (India) Ltd. | Subsidiary | Electronics: Systronics and Telerad divisions | Received electronics division 2010 |
Suvik Hitek Pvt. Ltd. | Wholly owned subsidiary | Ethical/generic products | Acquired (date n.d.) |
Haryana Containers Ltd. | Subsidiary | Legacy packaging entity | Activity level not disclosed |
Mautik Exim Ltd. | Subsidiary | Trading/exports | Activity level not disclosed |
Vovantis Laboratories Pvt. Ltd. | JV (per Groww company summary); listed as a subsidiary in older profiles | USFDA-approved plant at Ranoli; novel drug delivery; US/EU focus | Classification discrepancy across sources |
CoSara Diagnostics Pvt. Ltd. | JV (Synbiotics and Co-Diagnostics, est. 2017) | Molecular diagnostics (PCR) manufacture and sale, India first | SPAC exploration since Nov 2025 |
Income Statement and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 196.7 | 170.3 | 173.6 | 196.2 | 202.3 |
Total income incl. other income (as reported) | 238.8 | 182.8 | 183.9 | 207.6 | 217.4 |
Cost of revenue | 116.4 | 104.3 | 102.6 | 118.3 | 121.4 |
Gross profit | 81.3 | 66.7 | 71.8 | 79.0 | 81.1 |
SG&A | 26.0 | 25.7 | 27.9 | 30.8 | 32.6 |
Operating income (StockAnalysis basis) | 25.9 | 10.2 | 8.2 | 12.6 | 19.0 |
EBITDA before other income (Screener operating profit) | 25 | 8 | 6 | 9 | 12 |
Interest expense | 1.7 | 2.4 | 5.7 | 4.2 | 4.1 |
Share of profit of JVs/associates | 6.4 | -0.7 | -2.7 | 0.6 | 0.4 |
Profit before tax (Screener) | 54 | 15 | 7 | 5 | 19 |
Net profit (consolidated) | 47.2 | 11.4 | 5.7 | 4.9 | 17.8 |
EPS basic and diluted (INR) | 6.16 | 1.49 | 0.74 | 0.64 | 2.32 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | 19.7 | -13.5 | 1.9 | 13.2 | 2.6 |
Gross margin | 41.3 | 39.2 | 41.3 | 40.3 | 40.1 |
Operating margin (StockAnalysis basis) | 13.1 | 6.0 | 4.7 | 6.4 | 9.4 |
EBITDA margin before other income (Screener basis) | 12.7 | 4.7 | 3.5 | 4.6 | 5.9 |
Net margin | 24.0 | 6.7 | 3.3 | 2.5 | 8.8 |
Income Statement
| Metric (INR Cr) | Q1FY2025 | Q2FY2025 | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|---|---|---|---|
Revenue from operations | 40.70 | 44.70 | 45.97 | 64.81 | 40.34 | 44.45 | 52.00 | 65.49 | 43.56 |
Operating profit (pre-other income) | 0.47 | 2.54 | -0.70 | 5.30 | 1.46 | 0.36 | 4.08 | 5.70 | 4.54 |
Other income | 2.30 | 2.80 | 5.76 | -5.37 | 8.36 | 1.62 | 1.94 | 3.02 | 2.03 |
PBT | 0.84 | 3.11 | 2.93 | -2.05 | 7.93 | -0.04 | 4.36 | 6.25 | 4.68 |
Net profit | 0.35 | 2.62 | 2.23 | -0.27 | 8.22 | -0.56 | 3.64 | 6.50 | 3.98 |
Liquidity & Coverage Ratios
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 230.5 | 245.7 | 249.5 | 271.7 | 281.1 |
Cash and equivalents | 12.1 | 10.1 | 10.8 | 4.9 | 6.2 |
Cash plus short-term investments | 25.5 | 25.2 | 26.7 | 8.7 | 16.6 |
Total debt (derived, incl. leases) | 26.7 | 45.2 | 46.1 | 50.9 | 56.5 |
Net debt | 1.3 | 20.0 | 19.4 | 42.2 | 39.9 |
Goodwill | 24.5 | 24.5 | 24.5 | 24.5 | 24.5 |
Other intangibles | 0.04 | 0.02 | 0.02 | 0.01 | 1.83 |
Property, plant and equipment | 45.4 | 64.3 | 63.0 | 62.8 | 66.2 |
Long-term investments | 32.6 | 35.1 | 34.3 | 48.4 | 45.2 |
Trade and other receivables | 43.9 | 30.5 | 30.1 | 51.1 | 55.4 |
Inventory | 15.1 | 17.4 | 16.2 | 23.6 | 22.2 |
Total current assets | 120.2 | 110.9 | 118.5 | 118.6 | 125.0 |
Working capital | 14.7 | 8.1 | 16.2 | -1.9 | 26.5 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 11.47 | 5.73 | 8.89 | -17.62 | 13.40 |
Capital expenditure | 15.71 | 20.67 | 2.91 | 2.72 | 4.24 |
Free cash flow | -4.24 | -14.94 | 5.98 | -20.34 | 9.16 |
Investing cash flow | 5.08 | -16.78 | -5.30 | 13.26 | -10.26 |
Financing cash flow | -19.19 | 9.09 | -2.95 | -1.52 | -1.85 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Cash interest paid | 1.57 | 4.65 | 3.76 | 4.04 | 3.81 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROA (%) | 20.5 | 4.7 | 2.3 | 1.8 | 6.3 |
Asset turnover (x) | 0.85 | 0.69 | 0.70 | 0.72 | 0.72 |
Current ratio (x) | 1.14 | 1.08 | 1.16 | 0.98 | 1.27 |
Interest coverage, operating income / interest (x) | 15.5 | 4.3 | 1.4 | 3.0 | 4.7 |
Net debt / operating income (x) | 0.05 | 1.96 | 2.38 | 3.34 | 2.10 |
Geography Overview
| Geography | Evidence | Assessment |
|---|---|---|
India (domestic) | Electronics (Systronics, Telerad) is India-focused. Sarabhai Chemicals is a domestic branded business. The CoSara initial focus is India. | Very likely the majority of revenue; exact share not publicly disclosed |
United States | Asence Inc. is a US-incorporated trading subsidiary. Vovantis has a USFDA-approved plant targeting the US. Synbiotics is USFDA-inspected. | Material export channel; amount not disclosed |
Europe | Vovantis targets EU markets (Groww company summary). | — |
Semi-regulated markets (Africa, Asia, LatAm) | Asence registrations target semi-regulated markets (FY2026 DR). | — |
“—” = not publicly disclosed.
Share Price & Returns
| Reference point | Price (INR) | Source |
|---|---|---|
14 May 2021 (Amphotericin rally) | 40.05 | Business Standard |
2024 peak (52-week high reported Aug 2025) | 68.0 | Screener |
6 May 2025 | 35.40 | Simply Wall St |
19 Dec 2025 | 27.91 | ICICI Direct |
6 Feb 2026 (52-week low INR 23.12) | 25.69 | Bajaj Finserv |
18 Mar 2026 | 28.00 | 5paisa |
21 Jul 2026 | 31.99 | StockAnalysis |
7 Aug 2026 (post-clarification spike; 52-week high about INR 50) | 47.00 | Google Finance |
25 Sep 2026 | 41.09 | IIFL |
17 Oct 2026 (implied from INR 289.6 crore market cap) | 37.8 | Kotak Neo |
Return (approximate, price only) | Value | — |
1-year (Oct 2025 about INR 34–35 → Oct 2026 about INR 38) | about +8% to +11% | — |
3-year | Not precisely verified. Simply Wall St reported +11.5% for 3 years to May 2025. | — |
5-year (May 2021 about INR 40 → Oct 2026 about INR 38) | about −5%. Simply Wall St reported +107% for 5 years to May 2025, from a pre-Covid low base. | — |
Valuation Multiples
| Multiple | ASE | Note |
|---|---|---|
Market cap (INR Cr) | about 290 | Kotak Neo, 17 Oct 2026 |
P/E (TTM; TTM EPS about INR 1.48 after Q1 FY2027) | about 25.5 | Computed: TTM net profit 13.56 crore = 17.80 − 8.22 + 3.98. Screener TTM profit INR 13.6 crore. |
P/E on FY2026 EPS (INR 2.32) | about 16.3 | Computed |
P/B (book value INR 20.66) | about 1.83 | Computed |
EV (market cap + net debt INR 39.9 crore) | about 330 | Computed |
EV / Sales (FY2026) | about 1.63 | Computed |
EV / EBITDA (operating income + D&A INR 22.9 crore) | about 14.4 | Computed. MarketInOut showed 10.7x at a lower price (August 2026). |
Industry P/E reference | 34.4 | Groww "Industry P/E" |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. Covered by 0 analysts (Simply Wall St). MarketsMojo's automated rating has repeatedly been "Sell" (2026), later "Hold" (September 2026). |
Dividend history and policy | No dividend 2017–2026 (finanzen.ch); FY2026 none recommended. No formal dividend policy disclosed. |
Credit ratings (Moody's / S&P / Fitch) | None. No domestic agency rating (CRISIL/ICRA/CARE) identified in sources reviewed. |
Debt maturity profile | Not publicly disclosed. Debt of about INR 51–57 crore, skewed toward short-term working-capital lines. |
Equity capital changes | None. Shares outstanding constant at 76,633,296 since at least FY2017 (equity capital INR 76.63 crore). |
Liquidity | Average daily volume about 176,000 shares (Google Finance, August 2026); retail-dominated |
Analyst Conclusions
Management guidance and consensus
No guidance and no consensus exist. The Directors' Report frames the outlook qualitatively. It points to the subsidiary/JV strategy, the scale-up of the Ranoli oncology/API plant, international registrations through Asence, domestic specialty-brand focus and electronics continuity.
Bull case
-
Operating inflection is underway. Consolidated OPM rose to 10.4% in Q1 FY2027 from 3.6%, and Q3–Q4 FY2026 OPMs were 7.9–8.7%. If the Ranoli plant's utilisation continues to improve, core EBITDA could more than double from FY2026's INR 12 crore (Screener basis) without heroic revenue assumptions. Gross margin is already stable at about 40%.
-
Electronics is an under-appreciated cash generator. The segment grew about 10% CAGR to INR 91.8 crore and has stayed profitable through pharma downturns. On standalone multiples it could anchor a meaningful part of the INR 290 crore market cap.
-
Hidden asset value and catalysts. Possible sources include a CoSara SPAC (Maxim engaged, November 2025), USFDA-approved/inspected capacity (Vovantis, Synbiotics), land held at INR 12.3 crore book (StockAnalysis), and long-term investments of INR 45 crore. At 1.8x book, any monetisation event could re-rate the stock.
Bear case
-
Profits are not core. Other income was about 78% of FY2026 PBT. Q1 FY2027 shows how quickly reported profit falls (−52%) when one-offs disappear. On core earnings, the stock trades well above its headline P/E.
-
Structural stagnation. Revenue CAGR was about 0.7% over four years. R&D is about 0.01% of sales. Sub-scale positions compete against far larger API and instrument companies. Three decades of "rebuild" have yet to produce a sustained growth record.
-
Governance and partner risk. Promoter holding is 31.35% and executive control sits with the family. Shareholders approved Section 185 loans to related entities (July 2026). There has been no dividend in more than ten years. The key optionality asset (CoSara) depends on Co-Diagnostics, which reported a USD 46.9 million loss and needed a reverse split.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| ~5 Nov 2026 | Q2 FY2027 results | Whether OPM stays above 8% in a seasonally weak quarter; Pharma segment result turning positive |
| 1 Dec 2026 | Ranoli shareholder plant visit | Utilisation, customer qualifications, regulatory filings (DMFs) |
| Feb 2027 | Q3 FY2027 results | Electronics order intake ahead of Q4 |
| Any time | CoSara SPAC announcement | Definitive agreement, valuation, ASE/Synbiotics stake after the merger |
| Ongoing | Section 185 related-party loans | Amounts disbursed and terms (quarterly RPT disclosures under Reg. 23(9)) |
| May 2027 | FY2027 results | Core EBITDA vs FY2026's INR 12 crore; other-income dependence; FCF |
| Ongoing | USFDA inspections at Synbiotics and Vovantis | Inspection outcomes (EIR, Form 483) |
| Ongoing | Debt trajectory | Short-term borrowings and receivable days |
Analyst verdict
Ambalal Sarabhai Enterprises is a case study in legacy-brand optionality wrapped around a modest operating core. On disclosed facts, the group generates about INR 200 crore of revenue at a stable 40% gross margin. Weak scale economics convert that into only about 6% EBITDA before other income. Headline profit of INR 17.8 crore in FY2026 overstates recurring earning power, because other income contributed most of PBT. The Q1 FY2027 print showed both sides of the story. Operating margin improved sharply to 10.4%, while reported profit halved as non-operating gains disappeared.
At about INR 290 crore market cap (about 1.8x book, about 14x EV/EBITDA, about 25x trailing earnings), the market is already paying for some improvement. On the positive side, there is evidence of an operating turn. The last three reported quarters each delivered OPM above 7.8%. Electronics is a resilient, growing, profitable business. FY2026 restored positive free cash flow and working capital.
Several factors restrain conviction. Revenue has barely grown since FY2022. R&D is effectively nil. Leverage has risen. Promoter ownership is low and institutions are absent. Recent AGM approvals for related-party loans add governance noise. The most-discussed catalyst, a CoSara SPAC, depends on a financially stressed US partner and has no terms or timetable a year after it was announced.
Our synthesis is that ASE is a speculative, event-driven micro-cap rather than a compounding pharma franchise. The investment case improves materially only if three things happen together: OPM holds at or above 8–10% through a non-seasonal quarter; the Ranoli plant shows tangible regulated-market customer wins; and related-party cash flows are transparent and limited. Absent these, the stock is likely to keep trading on newsflow and liquidity spikes, as it did in August 2026, rather than on fundamentals. The Q2 FY2027 results (expected 5 November 2026) and the 1 December 2026 plant visit are the next tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure | Age / DOB | Background | Source |
|---|---|---|---|---|---|
Kartikeya V. Sarabhai | Executive Chairman (Executive Director; Chairperson) | Director since 30 July 1992; current appointment from 1 April 2024 | Born 27 Nov 1947 (age 78) | Son of Dr. Vikram Sarabhai; Chairman since mid-1990s; led liability settlement and group rebuild; retires by rotation and offered re-appointment (FY2026 AGM) | NSE governance filing, April 2026; Directors' Report |
Mohal K. Sarabhai | Managing Director (KMP) | Additional Director 24 Aug 2023; MD since 21 Sep 2023 | Born 5 Oct 1970 (age 56) | Long association with the company; previously CEO of several group companies (board outcome, 24 Aug 2023); architect of Asence | NSE filing; BSE filing; Simply Wall St |
Ms. Chaula Shastri | Whole-time Director | On board by Nov 2019 | — | Executive director (administration/communications experience per board disclosure) | BSE filing, Nov 2019; Directors' Report |
Satyen R. Dave | Independent Director | From 1 April 2024 | — | — | MarketScreener; Directors' Report |
Four further Independent Directors | Independent | Mostly from the March 2024 refresh | — | Names not captured in sources reviewed | Directors' Report |
Two Nominee Directors | Nominee | — | — | Nominating institution not disclosed in sources reviewed | Directors' Report |
“—” = not publicly disclosed.
Executive Leadership Team
| Executive | FY2020 (INR Lakh) | FY2021 (INR Lakh) | Note |
|---|---|---|---|
Kartikeya V. Sarabhai | 40.25 | 41.91 | Chairman & WTD remuneration (RPT disclosure, BSE, July 2021) |
Mohal K. Sarabhai | 52.80 | 61.76 | Shown then as "relative of director"; amounts likely paid via the group |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Sarabhai Holdings Pvt. Ltd. (promoter) | 19,742,348 | 25.76 |
Mallika Vikram Sarabhai (promoter group) | 127,073 | 0.17 |
Kartikeya Vikram Sarabhai | 126,346 | 0.16 |
Sarabhai Management Corporation Pvt. Ltd. | 91,634 | 0.12 |
Mohal Kartikeya Sarabhai | 51,387 | 0.07 |
Samvit Kartikeya Sarabhai | 44,540 | 0.06 |
Other promoter group entities (20 holders) | about 3.84 million | about 5.01 |
Total promoter and promoter group (26 holders) | 24,021,492 | 31.35 |
Public (169,604 holders) | 52,611,804 | 68.65 |
Shareholding Pattern
| Category trend (%) | Jun2022 | Mar2023 | Mar2024 |
|---|---|---|---|
Promoters | 30.76 | 30.77 | 30.77 |
Institutions | 0.01 | 0.01 | 0.01 |
Bodies corporate | 2.56 | 1.67 | 5.81 |
Individuals | 62.23 | 61.64 | 57.92 |
NRIs | 1.63 | 1.73 | 1.49 |
Competitive Landscape
Competitors by Segment
| Segment / niche | Competitor | Type | Relative positioning vs ASE |
|---|---|---|---|
Amphotericin B (API and formulations) | — | API | Synbiotics' claim to be India's only Amphotericin B API maker gives domestic supply-security value |
Amphotericin B formulations (India) | Bharat Serums & Vaccines; Sun Pharma; Cipla and other licensees of liposomal/lipid formulations | Formulators (customers and competitors) | ASE is mainly a supplier upstream of these players |
Oncology APIs | MSN Laboratories, Hetero, Natco Pharma, Shilpa Medicare, Laurus Labs (oncology APIs) | API manufacturers | Vastly larger scale, regulatory filings and DMF libraries; Asence is a new entrant |
Domestic oncology brands | Natco, Intas, Dr. Reddy's, Zydus, Cipla | Branded generics | Sarabhai Chemicals is a small niche player |
Fertility / IVF products | Sun Pharma, Bharat Serums & Vaccines, Ferring (India), Intas | Branded | Niche share |
Vitamin C / effervescent | Various nutraceutical CMOs | Contract manufacturers | Niche |
Small-cap pharma peers (valuation benchmarks) | Balaxi Pharmaceuticals; Alpa Laboratories | Listed micro/small caps | Used by Tijori as benchmark peers. Five-year average ROE: ASE 19.1%, Balaxi 27.3%, Alpa 8.1% (Tijori). |
Analytical / lab instruments (India) | Shimadzu, Thermo Fisher Scientific, Agilent, PerkinElmer/Revvity (premium); Labindia, Electronics India, Elico and other domestic makers (value) | Instruments | Systronics competes in the value/education segment with import-substitute products |
Broadcast equipment distribution | Other authorised broadcast distributors and system integrators | Distribution | Telerad recognised as a leading regional distributor (West, 2025) |
Molecular diagnostics (CoSara) | Molbio Diagnostics (Truenat), Mylab Discovery, Roche, Abbott, Cepheid | Diagnostics | CoSara is pre-scale; Molbio dominates India point-of-care PCR for TB |
Healthcare micro-cap comparables (market cap) | Asarfi Hospital (about INR 393 crore market cap); QMS Medical Allied Services | Listed peers | Univest comparison: ASE market cap about INR 316 crore |
Peer Comparison FY2026
| Metric | ASE FY2026 | Note |
|---|---|---|
Revenue (INR Cr) | 202.3 | Large oncology API peers report multi-thousand-crore revenue |
Revenue growth (%) | 2.6 | Below Indian pharma sector growth (typically high single to low double digits) |
EBITDA margin before other income (%) | 5.9 | Well below the typical 15–25% for scaled Indian API/formulation companies |
R&D intensity (%) | about 0.01 | Scaled Indian pharma typically spends 5–9% |
Net margin (%) | 8.8 | Boosted by other income |



